Journal of neural transmission (Vienna, Austria : 1996)

Using the diabetes drug liraglutide to treat Alzheimer's symptoms in rats with brain damage

Updated

Abstract

-treated rats exhibited significant cognitive deficits and reduced neurogenesis following treatment.

  • Rats treated with streptozotocin showed impaired spatial learning in the Morris water maze and deficits in fear-motivated memory in the passive avoidance test.
  • These cognitive impairments were associated with reduced adult neurogenesis in the hippocampus and downregulated expression of insulin and glucose metabolism-related genes.
  • treatment did not reverse cognitive deficits and worsened performance in the passive avoidance test.
  • Liraglutide partially restored dysregulated gene expression but also stimulated neuroinflammation in treated rats.
  • Further refined experimental designs may clarify the therapeutic potential of liraglutide.

Simplified

Key figures

Fig. 1
Timeline of and treatments with behavioral tests and sample collection in rats
Anchors the experimental sequence linking drug treatment timing with behavioral and molecular assessments
702_2025_2979_Fig1_HTML
  • Panel A
    STZ 3 mg/kg injections at 4 months of age
  • Panel B
    Liraglutide 0.3 mg/kg/day subcutaneous treatment started 2 months after STZ for 1 month
  • Panel C
    behavioral tests conducted before and after liraglutide treatment at 6 and 7 months
  • Panel D
    Passive avoidance test performed after the final Morris Water Maze test
  • Panel E
    Blood plasma sampling under general anesthesia prior to sacrifice
  • Panel F
    Sacrifice followed by and analyses
Fig. 2
Body weight and relative weight change in and control rats during treatment
Highlights liraglutide’s consistent and stronger weight loss effect in STZ-icv rats compared to controls during treatment
702_2025_2979_Fig2_HTML
  • Panel A
    Absolute body weight over 4 weeks showing liraglutide (LIR) causes rapid and sustained weight loss in both STZ-icv and control rats
  • Panel B
    Relative body weight change (%) over 4 weeks with liraglutide groups showing greater weight loss compared to saline () controls, and groups showing more pronounced weight loss than VEH within SAL and LIR treatments
Fig. 3
Blood glucose levels in and rats treated with or at 1.5 and 4 weeks
Frames blood glucose stability over time showing no clear changes between LIR and SAL treatments in both VEH and STZ rats
702_2025_2979_Fig3_HTML
  • Panels VEH and STZ at 1.5 weeks
    Blood glucose levels measured in VEH and STZ groups treated with SAL or LIR; levels appear similar across all groups
  • Panels VEH and STZ at 4 weeks
    Blood glucose levels measured in VEH and STZ groups treated with SAL or LIR; levels appear similar across all groups
Fig. 4
Spatial learning performance in rats before and after treatment in a water maze task
Highlights longer swim distances and more in rats compared to controls after treatment, spotlighting spatial learning deficits
702_2025_2979_Fig4_HTML
  • Panels A and B
    Swim distance over five training days before and after treatment; STZ/ group appears to have longer swim distances than other groups after treatment
  • Panels C and D
    Number of search errors over five training days before and after treatment; STZ/SAL group shows higher mean search errors than other groups after treatment
  • Panels E and F
    (time to find hidden platform) over five training days before and after treatment; no clear differences in mean escape latency between groups after treatment
Fig. 5
Spatial reference memory in rats before and after treatment
Frames spatial memory performance before and after treatment, highlighting time spent near the target appears lower after treatment in rats
702_2025_2979_Fig5_HTML
  • Panel A
    Number of entries into the before and after liraglutide (LIR) or saline () treatment in vehicle () and streptozotocin (STZ) groups
  • Panel B
    Time spent in the target quadrant before and after liraglutide (LIR) or saline (SAL) treatment in VEH and STZ groups, with a dashed line indicating chance level
1 / 5

Full Text

What this is

  • This research investigates the effects of (), an antidiabetic drug, on cognitive deficits in a rat model of sporadic Alzheimer's disease (sAD).
  • () intracerebroventricular injections create an insulin-resistant brain state, mimicking sAD symptoms.
  • The study assesses 's impact on spatial learning, adult neurogenesis, and gene expression related to insulin signaling and neuroinflammation.

Essence

  • treatment did not reverse cognitive deficits in -icv treated rats but partially restored some dysregulated gene expressions associated with insulin signaling and neuroinflammation.

Key takeaways

  • treatment did not improve spatial learning or memory in -icv treated rats, indicating a lack of cognitive recovery.
  • Gene expression related to insulin signaling and glucose metabolism was partially restored in the prefrontal cortex after treatment, suggesting some neurobiological benefits.
  • treatment stimulated neuroinflammation, complicating its potential therapeutic role in Alzheimer's disease.

Caveats

  • The study did not observe significant cognitive improvements, which may limit the interpretation of 's efficacy in treating Alzheimer's-related deficits.
  • The potential for increased neuroinflammation with treatment raises concerns about its safety and long-term effects in Alzheimer's models.

Definitions

  • Streptozotocin (STZ): A chemical that induces insulin resistance and cognitive deficits, used to model sporadic Alzheimer's disease in animal studies.
  • Liraglutide (LIR): An antidiabetic medication that acts as a glucagon-like peptide-1 receptor agonist, showing potential neuroprotective effects.

Simplified

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free